Open AccessReal-life experience of tofacitinib in patients with treatment-resistant rheumatoid arthritis: 5 -year follow up: Monocentric experience
Author(s) -
Özlem Pehlivan
Publication year - 2022
Publication title -
i̇stanbul kuzey klinikleri
Language(s) - English
Resource type - Journals
ISSN - 2148-4902
DOI - 10.14744/nci.2022.05863
Subject(s) - medicine , tofacitinib , rheumatoid arthritis , erythrocyte sedimentation rate , rheumatology , tocilizumab , visual analogue scale , surgery
The present study aims to assess the short- and long-term effects of tofacitinib (TOFA) therapy on efficacy, safety, and drug retention rate patients with rheumatoid arthritis (RA) refractory to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and/or biological disease-modifying anti-rheumatic drugs (bDMARDs).